Xencor (NASDAQ:XNCR) Sets New 52-Week Low – Should You Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $10.55 and last traded at $10.81, with a volume of 165586 shares changing hands. The stock had previously closed at $11.23.

Analyst Ratings Changes

Several research firms have weighed in on XNCR. Wells Fargo & Company dropped their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.38.

Xencor Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm’s 50-day moving average price is $15.56 and its 200-day moving average price is $20.08. The stock has a market cap of $748.38 million, a P/E ratio of -3.32 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Xencor

Institutional investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in shares of Xencor in the third quarter valued at $540,000. Barclays PLC raised its position in Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Xencor in the third quarter worth about $362,000. Jane Street Group LLC boosted its position in shares of Xencor by 18.6% during the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock valued at $3,387,000 after buying an additional 26,473 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock worth $29,273,000 after buying an additional 17,658 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.